Human Papillomavirus Infection and Awareness of Human Pappillomavirus Vaccines among Various Ethnicities in Libya

Salma Korbag; Issa Korbag

doi:10.15850/amj.v8n3.2250

Human Papillomavirus Infection and Awareness of Human Pappillomavirus Vaccines among Various Ethnicities in Libya

Salma Korbag, Issa Korbag

Abstract

Background: Human papillomavirus (HPV) plays a role in increasing the risk of cervical cancer and other cancers. This study aimed to explore the incidence of HPV infection among various ethnicities in Libya. Furthermore, awareness and knowledge of HPV vaccines in the community were explored.

Methods: A descriptive study was conducted to present HPV infection among cancer cases using the National Cancer Registry of Libya year 2011-2020, including gender, skin color, and ethnicity. Furthermore, awareness and knowledge of the HPV vaccines were assessed using questionnaires distributed through social media. Data were presented in percentage.

Results: In total, there were 33,526 (58.1%) infected HPV-related cancers out of 57,620 cancer cases, of whom 25,296 (75.4%) were women and 8,230 (24.6%) were men. Based on cancer sites, the incidence of HPV-related cancers among whites was higher (>63% and more) than blacks except for anal cancer, of which blacks had a slightly higher incidence (54%) in females and 57% in males). Based on ethnicity, native Libyans such as Tabu, Touareg, and Berbers had different cancer sites. Moreover, the knowledge and awareness about HPV and related cancers were very poor among the population in Libya.

Conclusions: Although HPV cancers represent a high percentage of cancer burdens among Libyans, awareness and knowledge on HPV and related cancer are lacking. Better education and provision of the HPV vaccines for future generations may eliminate and reduce HPV-related cancers.

Keywords

Anal cancer, cervical cancer, HPV, Libya, sexually transmitted disease

Full Text:

PDF

References

Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008;198(6):827–35.

Korbag S, Korbag I. A new study biological role of HPV infection, oral contraceptive use, sex hormones and bisphenol A and increase rate cancer of cervical in Libya. J. Med Chem Sci. 2020;3(4):354–62.

Petrosky E, Bocchini Jr. JA., Hariri S, Chesson H, Curtis CR, Saraiya M, et al., Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11): 300–4.

Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017;40(2):80–5.

Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007;45(2–3):107–14.

Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014;10(7):2109–11.

Bharadwaj M, Hussain S, Nasare V, Das BC. HPV & HPV vaccination: issues in developing countries. Indian J Med Res. 2009;130(3):327–33.

St Laurent J, Luckett R, Feldman S. HPV vaccination and the effects on rates of HPV-related cancers. Curr Probl Cancer. 2018; 42(5):493–506.

Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males—advisory committee on immunization practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60(50):1705–8.

Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006; 24 Suppl 3:S3/11–25.

McBride KR, Singh S. Predictors of adults’ knowledge and awareness of HPV, HPV-associated cancers, and the HPV vaccine: implications for health education. Health Educ Behav. 2018;45(1):68–76.

Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–26.

Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3:S3/42–51.

Wilkin T, Lee JY, Lensing SY,Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010; 202(8):1246–53.

Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127–34.

Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue J Adolesc Health. 2010;46(4 Suppl):S12–9.

Wendland EM, Kops NL, Comerlato J, Horvath JDC, Bessel M, Sperb D, et al. STOP HPV study protocol: a nationwide case-control study of the association between oropharyngeal cancer and human papillomavirus (HPV) infection in Brazil. BMJ Open. 2020;10(1):e031602.

Signorelli C, Odone A, Ciorba V, Cella P, Audisio RA, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962–82.

Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines. 2014;13(8):1027–38.

DOI: https://doi.org/10.15850/amj.v8n3.2250